Our results showed that KLK2 expression is largely homogeneous across disease stages in prostate cancer, including advanced prostate cancer, and as such, KLK2 presents unique opportunities for the development of novel therapies in all stages of prostate cancer. The gene discussed is KLK2; the disease is prostate carcinoma.